That sale was by JNJ's investment arm, not by the R&D division of them. May has arrived, keep an eye on May 12 (ASCO abstracts), May 20 (JNJ's investor's day) and end of May (ASCO). Think we will be pleasantly surprised. This stock is going much higher during 2015.
Although it has seen a terrific run over the past year there is still a huge upside potential. After tuesday's results analysts increased their 12 months target to between DK 530 to 670. That's versus today's close of DK 446. And they are basing this on Dara only, not giving any value to the other developments in the pipeline. Some think that we shall see DK 750 by year-end and another double by 2017.